1. Home
  2. BCRX

as 06-13-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

Founded: 1986 Country:
United States
United States
Employees: N/A City: DURHAM
Market Cap: 1.3B IPO Year: 1994
Target Price: $14.00 AVG Volume (30 days): 3.7M
Analyst Decision: Strong Buy Number of Analysts: 7
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.07 EPS Growth: N/A
52 Week Low/High: $4.03 - $8.04 Next Earning Date: 08-01-2024
Revenue: $355,395,000 Revenue Growth: 22.68%
Revenue Growth (this year): 23.9% Revenue Growth (next year): 18.03%

BCRX Daily Stock ML Predictions

Stock Insider Trading Activity of BioCryst Pharmaceuticals Inc. (BCRX)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
LEVIN ALAN G BCRX Director May 30 '24 Buy $6.36 7,861 $49,995.96 44,951 SEC Form 4
MILANO VINCENT BCRX Director May 20 '24 Buy $6.25 15,000 $93,750.00 66,997 SEC Form 4
Doyle Anthony BCRX Chief Financial Officer May 14 '24 Buy $5.57 36,300 $202,191.00 266,744 SEC Form 4
Gayer Charles K BCRX Chief Commercial Officer May 13 '24 Buy $5.47 30,000 $164,100.00 307,533 SEC Form 4
Stonehouse Jon P BCRX President & CEO May 13 '24 Buy $5.55 30,000 $166,500.00 1,127,770 SEC Form 4
Galson Steven K BCRX Director May 13 '24 Buy $5.49 21,940 $120,450.60 51,551 SEC Form 4

Share on Social Networks: